Here are the 8-K filings from Cerenome, Inc. (CNSY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow CNSY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNSY filings page.
Cerenome, Inc. (CNSY) updated its corporate presentation on September 30, 2026, covering CNSide diagnostic commercialization and REYOBIQ clinical programs. As of that date, CNSide had 24 commercial ordering institutions and 43 ordering providers; commercial tumor-cell enumeration (TCE) volume was 362 specimens year to date, with 97% from 15 institutions ordering in two or more separate months. The company reported 158 million contracted covered lives and a proprietary reimbursement code effective July 1, 2026. The Medicare rate was expected to take effect January 1, 2027.
Modeled six-month leptomeningeal metastasis care costs were $717,000 under current standard of care, $480,000 with earlier CNSide confirmation and optimized management, and $380,000 with optimized management and favorable treatment-cost assumptions. In a 15-patient Phase 2 study of REYOBIQ, median overall survival was 13 months and median progression-free survival was 11 months, compared with stated standard-of-care figures of 8 and 4 months, respectively. ReSPECT-GBM was enrolling, with Phase 2 enrollment completion in Q4 2026 and topline data projected for the first half of 2027.
Cerenome, Inc. (CNSY) has arranged a senior secured convertible note and royalty-based financing to support its CNS oncology platform and CNSide diagnostics business. The company agreed with an institutional investor to issue senior secured convertible notes with an aggregate original principal amount of $21,276,596, split into Initial Notes of $3,191,489, Second Notes of $2,127,660, and Additional Notes of $15,957,447. The Initial closing is expected on or about September 10, 2026, when Cerenome expects to receive gross proceeds of $3,000,000.
The notes carry a 6.0% original issue discount, accrue interest at 8.0% per year, mature one year after issuance, and are secured by a first‑priority lien on substantially all assets of Cerenome and its subsidiary CNSide. They are convertible into common stock at an initial price of $2.74 per share, with a $0.50 floor and ownership caps of 4.99% (or 9.99% at the investor’s election), plus an exchange cap tied to Nasdaq rules. In default, an alternate, discount-to-market conversion formula applies and redemption premiums, including a 120% cash redemption on a Change of Control, may be triggered.
On the Initial Closing Date, Cerenome and CNSide are expected to enter a Royalty Agreement under which CNSide will pay the investor a quarterly royalty of 2.5% of its gross revenues, capped each quarter at 2.5% of the unpaid note balance, until all note obligations are fully repaid. A Registration Rights Agreement will require Cerenome to submit resale registration statements for conversion shares within set deadlines. Management states that, considering this facility, other facilities, existing cash and expected CNSide sales and cash flow, forecasted cash runway now extends well into 2028.